CDKN1B and hepatocellular carcinoma: They demonstrated that the FOXO3A-p27Kip1 pathway in hepatocellular carcinoma cell lines was activated by treatment with Casticin, as well as downregulation of FOXM1 which decreases FOXO3A expression.